Suppr超能文献

与当代多标志物风险评分相比,NT-脑钠肽前体和肾功能对心力衰竭患者的预后影响

Prognostic impact of NT-proBNP and renal function in comparison to contemporary multi-marker risk scores in heart failure patients.

作者信息

Pfister Roman, Diedrichs Holger, Schiedermair Anne, Rosenkranz Stephan, Hellmich Martin, Erdmann Erland, Schneider Christian Alfons

机构信息

Department III of Internal Medicine, University of Cologne, Germany.

出版信息

Eur J Heart Fail. 2008 Mar;10(3):315-20. doi: 10.1016/j.ejheart.2008.01.009. Epub 2008 Mar 4.

Abstract

BACKGROUND

Multi-marker risk scores accurately predict prognosis in heart failure patients but calculation is complex.

AIMS

To compare the prognostic accuracy of the Seattle Heart Failure Survival Score (SHFS) and a model derived from the CHARM programme, with laboratory parameters NT-proBNP and glomerular filtration rate (GFR).

METHODS AND RESULTS

In a sample of 290 heart failure patients, 39 patients died, 22 were hospitalised with acute heart failure and 4 underwent urgent cardiac transplantation during a median follow-up of 498 days. NT-proBNP, GFR, CHARM and SHFS showed an AUC for an endpoint during 1-year of 0.80, 0.72, 0.79 and 0.69, respectively. The hazard ratio for an endpoint during follow-up was 2.1, 2.6, 1.9 and 2.1 per 1 SD increase of log NT-proBNP and CHARM and per 1 SD decrease of GFR and SHFS, respectively. In multivariate analysis, log NT-proBNP and GFR added independent prognostic information to CHARM and SHFS, respectively.

CONCLUSION

NT-proBNP and GFR independently predicted endpoint-free survival in systolic heart failure patients, with NT-proBNP being superior and equally predictive to the SHFS and CHARM score, respectively. Assessment of both laboratory markers can simplify prognostic stratification, addition to multi-marker scores should be evaluated.

摘要

背景

多标志物风险评分可准确预测心力衰竭患者的预后,但计算复杂。

目的

比较西雅图心力衰竭生存评分(SHFS)和源自CHARM研究项目的模型与实验室参数N末端B型利钠肽原(NT-proBNP)和肾小球滤过率(GFR)的预后准确性。

方法与结果

在290例心力衰竭患者样本中,在中位随访498天期间,39例患者死亡,22例因急性心力衰竭住院,4例接受了紧急心脏移植。NT-proBNP、GFR、CHARM和SHFS在1年内终点事件的曲线下面积(AUC)分别为0.80、0.72、0.79和0.69。随访期间终点事件的风险比,每log NT-proBNP和CHARM升高1个标准差分别为2.1、2.6、1.9和2.1,每GFR和SHFS降低1个标准差分别为2.1、2.6、1.9和2.1。在多变量分析中,log NT-proBNP和GFR分别为CHARM和SHFS增加了独立的预后信息。

结论

NT-proBNP和GFR独立预测收缩性心力衰竭患者无终点事件生存,NT-proBNP分别优于SHFS和CHARM评分且具有同等预测性。评估这两种实验室标志物可简化预后分层,多标志物评分的附加作用应予以评估。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验